GP2015 Etanercept — Competitive Intelligence Brief

GP2015 Etanercept (GP2015 Etanercept) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-α inhibitor (biosimilar). Area: Immunology.

phase 3 TNF-α inhibitor (biosimilar) TNF-α (tumor necrosis factor-alpha) Immunology Small molecule

Target snapshot

GP2015 Etanercept (GP2015 Etanercept) — Sandoz. GP2015 is a biosimilar of etanercept that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation and immune-mediated tissue damage.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GP2015 Etanercept TARGET	GP2015 Etanercept	Sandoz	phase 3	TNF-α inhibitor (biosimilar)	TNF-α (tumor necrosis factor-alpha)
CT-L03	CT-L03	Celltrion	phase 3	TNF-α inhibitor (biosimilar)	TNF-α
ABP 501	ABP 501	Amgen	phase 3	TNF-α inhibitor (biosimilar)	TNF-α
CT-P13	CT-P13	CMC Ambroise Paré	phase 3	TNF-α inhibitor (biosimilar)	TNF-α (tumor necrosis factor-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-α inhibitor (biosimilar) class)

1. Amgen · 1 drug in this class
2. CMC Ambroise Paré · 1 drug in this class
3. Celltrion · 1 drug in this class
4. Sandoz · 1 drug in this class